CR20110687A - Procedimientos de uso del factor liberador de corticotropina para el tratamiento de cancer - Google Patents

Procedimientos de uso del factor liberador de corticotropina para el tratamiento de cancer

Info

Publication number
CR20110687A
CR20110687A CR20110687A CR20110687A CR20110687A CR 20110687 A CR20110687 A CR 20110687A CR 20110687 A CR20110687 A CR 20110687A CR 20110687 A CR20110687 A CR 20110687A CR 20110687 A CR20110687 A CR 20110687A
Authority
CR
Costa Rica
Prior art keywords
procedures
cancer treatment
release factor
corticotropine
corticotropine release
Prior art date
Application number
CR20110687A
Other languages
English (en)
Inventor
Stephen Evans-Freke
Original Assignee
Stephen Evans Freke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43243708&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20110687(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Stephen Evans Freke filed Critical Stephen Evans Freke
Publication of CR20110687A publication Critical patent/CR20110687A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan en el presente documento procedimientos para tratar cáncer en un ser humano mediante la administración de CRF, opcionalmente en combinación con un segundo agente.
CR20110687A 2009-06-24 2011-12-20 Procedimientos de uso del factor liberador de corticotropina para el tratamiento de cancer CR20110687A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22005509P 2009-06-24 2009-06-24

Publications (1)

Publication Number Publication Date
CR20110687A true CR20110687A (es) 2012-05-18

Family

ID=43243708

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110687A CR20110687A (es) 2009-06-24 2011-12-20 Procedimientos de uso del factor liberador de corticotropina para el tratamiento de cancer

Country Status (20)

Country Link
US (1) US20120183536A1 (es)
EP (1) EP2349323A2 (es)
JP (1) JP2012530740A (es)
KR (1) KR20120124353A (es)
CN (1) CN102481342A (es)
AU (1) AU2010265081A1 (es)
BR (1) BRPI1012262A2 (es)
CA (1) CA2766322A1 (es)
CL (1) CL2011003248A1 (es)
CO (1) CO6480929A2 (es)
CR (1) CR20110687A (es)
EC (1) ECSP11011550A (es)
IL (1) IL216930A0 (es)
MX (1) MX2012000203A (es)
NI (1) NI201100228A (es)
PE (1) PE20120559A1 (es)
RU (1) RU2012102259A (es)
SG (1) SG176802A1 (es)
WO (1) WO2010149357A2 (es)
ZA (1) ZA201109508B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3679934B1 (en) * 2011-04-29 2024-06-05 The Penn State Research Foundation Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
EP3292494B1 (en) * 2015-05-05 2024-03-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Systems and methods for providing personalized radiation therapy
US11077126B2 (en) * 2017-04-06 2021-08-03 Shenyang Fuyang Pharmaceutical Technology Co., Ltd. Use of carrimycin and pharmaceutically acceptable salts of carrimycin in manufacturing medicament for treating and/or preventing tumor
CN110384710B (zh) * 2018-04-17 2023-01-10 沈阳福洋医药科技有限公司 一种用于预防和/或治疗疼痛的药物、组合产品及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415558A (en) 1981-06-08 1983-11-15 The Salk Institute For Biological Studies CRF And analogs
DE3209645A1 (de) 1982-03-17 1983-09-29 Dr.Ing.H.C. F. Porsche Ag, 7000 Stuttgart Vorrichtung zum regeln einer kraftfahrzeug-antriebseinheit
US4533654A (en) 1982-09-29 1985-08-06 The Salk Institute For Biological Studies Urotensin peptides
US4528189A (en) 1983-02-03 1985-07-09 The Salk Institute For Biological Studies Urotensin peptides
US4489163A (en) 1983-04-14 1984-12-18 The Salk Institute For Biological Studies rCRF and analogs
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
EP2259793A2 (en) * 2008-04-30 2010-12-15 Neutron Row Use of corticotropin-releasing factor for the treatment of cancer
WO2010057962A2 (en) * 2008-11-19 2010-05-27 Neutron Limited Crf conjugates with extended half-lives

Also Published As

Publication number Publication date
JP2012530740A (ja) 2012-12-06
EP2349323A2 (en) 2011-08-03
AU2010265081A1 (en) 2012-01-19
CL2011003248A1 (es) 2012-04-13
CA2766322A1 (en) 2010-12-29
RU2012102259A (ru) 2013-07-27
MX2012000203A (es) 2012-04-20
WO2010149357A2 (en) 2010-12-29
US20120183536A1 (en) 2012-07-19
CO6480929A2 (es) 2012-07-16
ZA201109508B (en) 2013-05-29
ECSP11011550A (es) 2012-04-30
NI201100228A (es) 2012-05-23
WO2010149357A3 (en) 2011-06-16
IL216930A0 (en) 2012-02-29
SG176802A1 (en) 2012-01-30
CN102481342A (zh) 2012-05-30
PE20120559A1 (es) 2012-05-21
BRPI1012262A2 (pt) 2016-04-05
KR20120124353A (ko) 2012-11-13

Similar Documents

Publication Publication Date Title
UY32882A (es) (heteroarilmetil) tiohidantoínas sustituidas
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
MX2013012253A (es) Conjugados novedosos de aglutinante-farmaco (adc) y su uso.
DOP2012000155A (es) Terapia combinada para el tratamiento del cancer y ensayos de diagnostico relacionados
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
CL2011003229A1 (es) Compuestos conjugados derivados de criptoficina; procedimiento de preparacion; y su uso para el tratamiento del cancer.
CO6620019A2 (es) Métodos de tratamiento de cander de vejiga
CR20110553A (es) Terapia complementaria contra el cáncer
GT201200123A (es) Nuevo uso antitumoral de cabazitaxel
CL2012002037A1 (es) Uso de agonista doble del glucagon-glp-1 como agente inotropico en el tratamiento de la cardiopatía o la disfuncion cardiaca
UY33396A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
UY33029A (es) Antagonistas de espiro-oxindol de mdm2
CL2013000016A1 (es) Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
MX2014000292A (es) Usos de inhibidores etiquetados hsp90.
CL2012001405A1 (es) Compuestos derivados de espiroindolinona-pirrolidinas; proceso de obtención; composicion farmaceutica; y uso en el tratamiento o profilaxis del cancer.
CO7200273A2 (es) Combinaciones farmaceúticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
CL2012002326A1 (es) Uso de una combinación de por lo menos un agente quimioterapéutico y una cantidad efectiva de un anticuerpo anti-vegf (factor de crecimiento endotelial vascular), porque sirve para preparar un medicamento útil en el tratamiento de cáncer ovárico; y su kit para tratar el cáncer ovárico sin tratamiento anterior en una paciente humana.
CO6741197A2 (es) Proteína de fusión robo1-fc para uso en el tratamiento del hepatocarcinoma
CO6761366A2 (es) Composiciones farmacéuticas para el tratamiento de glioma maligno
CR20110687A (es) Procedimientos de uso del factor liberador de corticotropina para el tratamiento de cancer
WO2013096335A8 (en) ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT
CO6731081A2 (es) Método para producir y usar un copolímero de carboximetilcelulosa sódica y gosipol
MX2010009697A (es) Tratamientos anticancerigenos mejorados.
UY35033A (es) Formulación en comprimidos de un inhibidor de la fosfatidilinositol 3-cinasa